Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 1;23(4):319-326.
doi: 10.1097/ACI.0000000000000922. Epub 2023 Jun 23.

New approaches in childhood asthma treatment

Riccardo Castagnoli  1   2 , Ilaria Brambilla  1   2 , Mattia Giovannini  3   4 , Gian Luigi Marseglia  1   2 , Amelia Licari  1   2
Affiliations
Review

New approaches in childhood asthma treatment

Riccardo Castagnoli et al. Curr Opin Allergy Clin Immunol. .

Abstract

Purpose of review: This review aims to summarize the most recent advances in asthma management, focusing on novel approaches to pediatric asthma.

Recent findings: In recent years, the therapeutic tools for pediatric asthma have expanded significantly for both the nonsevere and severe forms. The use of anti-inflammatory treatment, even for the mildest cases, and the withdrawal of symptomatic bronchodilation as monotherapy have been included in the most recent guidelines. Also, different biological therapies have revolutionized the therapeutical approach for severe uncontrolled asthma in children and adolescents.

Summary: With the expanding landscape of novel therapeutic approaches for pediatric asthma, further evidence is needed to help clinicians choose the best option for patients, particularly those with severe asthma. The identification of novel predictive biomarkers may also help pediatricians in selecting children and adolescents for innovative therapies.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Box 1
Box 1
no caption available
FIGURE 1
FIGURE 1
Suggested algorithm for selecting a biologic agent for pediatric severe asthma. Note: Agents ordered alphabetically within each group. EOS, serum eosinophils; FeNO, fractional exhaled nitric oxide. 1Omalizumab only for allergic asthma (all other agents can be considered for both allergic and nonallergic asthma). 2Dupilumab only if EOS less than 1500 cells/μl.
See this image and copyright information in PMC

References

    1. 2022 GINA Report, Global strategy for asthma management and prevention. 2023. Available at: https://ginasthma.org/gina-reports/[Accessed 17 April 2023]

    2. The GINA Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention. This article summarizes key recommendations from GINA 2022, and the evidence underpinning the new changes.

    1. Porsbjerg C, Melén E, Lehtimäki L, et al. . Asthma. Lancet 2023; 401:858–873. - PubMed

    2. In this Seminar, authors provide a clinically focused overview of asthma: epidemiology, pathophysiology, diagnosis, and management in children and adults.

    1. Saxena S, Rosas-Salazar C, Fitzpatrick A, Bacharier LB. Biologics and severe asthma in children. Curr Opin Allergy Clin Immunol 2023; 23:111–118. - PubMed
    1. Andrenacci B, Ferrante G, Roberto G, et al. . Challenges in uncontrolled asthma in pediatrics: important considerations for the clinician. Expert Rev Clin Immunol 2022; 18:807–821. - PubMed
    1. Ferrante G, La Grutta S. The burden of pediatric asthma. Front Pediatr 2018; 6:186. - PMC - PubMed

LinkOut - more resources